PhageTech

PhageTech Inc, founded in Irvine, California, is a development-stage company focused on revolutionizing early disease detection through its innovative bacteriophage substrate technology. The company's core mission is to create fast, accurate, and easy-to-use diagnostic systems that can detect diseases like cancer and infectious diseases at their earliest stages. PhageTech's primary product is the Virus BioResistor (VBR), a point-of-care diagnostic tool designed for use with various body fluids such as urine and blood. The company's vision is to expand healthcare access, improve patient outcomes, and reduce overall healthcare costs globally.

Notable figures associated with PhageTech include its team of pioneering scientists and medical professionals who are driving the innovation behind its diagnostic platform. The company has attracted significant interest from investors focused on healthcare technology. A key achievement for PhageTech is the commencement of clinical trials for the VBR, starting with bladder cancer screening. This milestone underscores the potential impact of their technology in transforming disease detection and management, promising to make significant strides in early diagnosis and treatment, thereby enhancing patient care and reducing healthcare expenditures.